Disclosed are method of enhancing perispinal perfusion in a patient suffering from reduced perfusion of the lower back through administration of T regulatory cells alone capable of stimulating angiogenesis directly or through enhancement of angiogenic activities of cellular therapies. Said cellular therapies possessing angiogenic activities include mesenchymal stem cells, hematopoietic stem cells and endothelial progenitor cells. In one embodiment of the invention, administration of T regulatory cells is performed that are expanded ex vivo. For certain embodiment of the invention T regulatory cells may be autologous or allogeneic.

Compositions, methods of treatment for liver disease such as liver fibrosis, compositions, and methods for the manufacture thereof, comprising a plurality of macrophages derived from human induced pluripotent stem cells (iPSCs), wherein the macrophages are polarized to a pro-inflammatory M1 phenotype and/or an anti-inflammatory M2 phenotype. Administration reduces fibrogenic gene expression and liver disease associated histological markers. The M1 macrophages express elevated CD80, TNF-? and IL-6. The M2 macrophages express elevated CD206, CCL17, and CCL22.

Disclosed is a composition containing a Lactobacillus fermentum strain, preferably a composition containing Lactobacillus fermentum GB-102 strain deposited with accession number KCTC 14105BP and natural killer cells, and the use of the strain for administration in combination with natural killer cells for the suppression of weight gain or the prevention and/or treatment of metabolic diseases, and the composition and the combination therapy have an effect of remarkably suppressing weight gain. The composition and the combination therapy can be easily used to control the body weight of a subject, and are useful in the fields of beauty, livestock, medicines, and the like, in particular, are useful in the fields of pharmaceutical compositions, food additives, health functional foods, and therapeutic agents for ameliorating, preventing and treating metabolic diseases including obesity.

The disclosure relates to populations of educated macrophages and monocytes generated ex vivo or in vivo, and methods of making and using the same using lipid A aminoalkyl glucosaminide phosphate molecules, such as CRX molecules or extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) stimulated with CRX molecules. Also described are EVs and methods for making and using the same from MSCs exposed to CRX.

The invention relates to agents and methods for treating or preventing inflammatory conditions or diseases.

Disclosed is a composition containing a Lactobacillus fermentum strain, preferably a composition containing Lactobacillus fermentum GB-102 strain deposited with accession number KCTC 14105BP and regulatory T cells, and the use of co-administration of the strain and regulatory T cells for the suppression of weight gain or the prevention and/or treatment of metabolic diseases. The composition and the combination therapy have an effect of remarkably suppressing weight gain. Therefore, the composition and the combination therapy can be easily used to control the body weight of a subject, and are useful in the fields of beauty, livestock, medicines, and the like, in particular, are useful in the fields of pharmaceutical compositions, food additives, health functional foods, and therapeutic agents for ameliorating, preventing and treating metabolic diseases.

The present invention discloses methods, compositions and devices for improving tissue regeneration by suppressing the effects of several proinflammatory cytokines such as TNF-? and IFN-?. Compositions and devices of this invention will generally include one or more anti-inflammatory agent(s) capable of reducing the level of TNF-?, IFN-?, or both. Methods for improving tissue regeneration in accordance with this invention will generally have the step of applying a composition or device of the invention to a site in need of the composition or device. Also disclosed are methods for forming composition and devices of the invention and pharmaceutical compositions comprising one or more anti-inflammatory agent(s) effective of inhibiting or reducing the levels of TNF-?, IFN-?, or both.

The present invention provides a method of inducing microglia cells from blood cells, comprising culturing the blood cells in the presence of interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF).

The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.

Methods are provided for the cell-based delivery of collagen VII for the treatment of epidermolysis bullosa.